Portfolio company
TRIANA Biomedicines
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops molecular glue therapeutics for patients with cancer and other diseases using a discovery platform and computational tools.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ternary Therapeutics
This company develops an artificial intelligence platform to design molecular glue therapeutics for healthcare providers and pharmaceutical partners to treat complex diseases.
Molecular Glue Labs
This company develops artificial intelligence software and infrastructure to design small-molecule drugs that reprogram protein networks to treat previously untreatable diseases.
Ternary Tx
Ternary Therapeutics develops an artificial intelligence platform to design molecular glue drugs for pharmaceutical companies targeting previously undruggable proteins linked to inflammatory diseases.
Neomorph
The company develops molecular glue degraders to target and eliminate disease-causing proteins for pharmaceutical partners and patients with neurological or immune diseases.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Auron Therapeutics
This company develops small-molecule drugs using an AI-powered platform to treat patients with cancer and inflammatory diseases.
Ten63 Therapeutics
This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.